CAR T-cell therapy for certain blood cancers after relapse
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these diagnoses: B-cell ALL (age 25 or younger), DLBCL (age 18–70), or PMBCL (age 18–70)
- Your cancer has come back or did not respond after two prior treatment lines
- Your overall health is good enough that you have a performance status score of 0 or 1 (rather than worse)
- You do not have uncontrolled or active infections, and you have enough organ function for treatment
- You have not had a blood clot that affected circulation within the last 6 months
- You likely have at least 3 months of life expectancy and no major health problems that could be worsened by immunosuppressing treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments, including an FDA-approved CAR T-cell therapy. The goal is to see if this new therapy can help when previous CAR T treatment has not worked.
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
This trial tests a new CAR T-cell therapy made locally for children and young adults with B-cell cancers that have come back or not responded to other treatments. The therapy uses your own immune cells, modified to find and attack cancer cells.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
This trial tests a new type of CAR T-cell therapy—a treatment that uses your own immune cells engineered to fight leukemia cells. It is designed for patients with B-cell acute lymphoblastic leukemia (ALL) that has come back or stopped responding to standard treatments, and whose leukemia cells have a specific marker called TSLPR.
This early-phase trial tests a lab-made immune cell treatment (CAR T-cells) aimed at T-cell leukemia that has come back or did not respond. It may help by targeting leukemia cells with a specific marker (CD7), especially in patients who failed standard treatment.
Hear when a new Primary Mediastinal Large B-cell Lymphoma (PMBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.